Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
Abstract This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NS...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e8525597104945a9b652438e850135a1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e8525597104945a9b652438e850135a1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e8525597104945a9b652438e850135a12021-12-02T12:30:27ZClinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients10.1038/s41598-017-02313-y2045-2322https://doaj.org/article/e8525597104945a9b652438e850135a12017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02313-yhttps://doaj.org/toc/2045-2322Abstract This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004–2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22–0.63) for those without cirrhosis and 0.54 (0.31–0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.Mei-Hsuan LeeChung-Feng HuangHsueh-Chou LaiChun-Yen LinChia-Yen DaiChun-Jen LiuJing-Houng WangJee-Fu HuangWen-Pang SuHung-Chih YangKwong-Ming KeeMing-Lun YehPo-Heng ChuangShih-Jer HsuChing-I HuangJung-Ta KaoChieh-Chang ChenSheng-Hung ChenWen-Juei JengHwai-I YangYong YuanSheng-Nan LuI-Shyan SheenChen-Hua LiuCheng-Yuan PengJia-Horng KaoMing-Lung YuWan-Long ChuangChien-Jen ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Mei-Hsuan Lee Chung-Feng Huang Hsueh-Chou Lai Chun-Yen Lin Chia-Yen Dai Chun-Jen Liu Jing-Houng Wang Jee-Fu Huang Wen-Pang Su Hung-Chih Yang Kwong-Ming Kee Ming-Lun Yeh Po-Heng Chuang Shih-Jer Hsu Ching-I Huang Jung-Ta Kao Chieh-Chang Chen Sheng-Hung Chen Wen-Juei Jeng Hwai-I Yang Yong Yuan Sheng-Nan Lu I-Shyan Sheen Chen-Hua Liu Cheng-Yuan Peng Jia-Horng Kao Ming-Lung Yu Wan-Long Chuang Chien-Jen Chen Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| description |
Abstract This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004–2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22–0.63) for those without cirrhosis and 0.54 (0.31–0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored. |
| format |
article |
| author |
Mei-Hsuan Lee Chung-Feng Huang Hsueh-Chou Lai Chun-Yen Lin Chia-Yen Dai Chun-Jen Liu Jing-Houng Wang Jee-Fu Huang Wen-Pang Su Hung-Chih Yang Kwong-Ming Kee Ming-Lun Yeh Po-Heng Chuang Shih-Jer Hsu Ching-I Huang Jung-Ta Kao Chieh-Chang Chen Sheng-Hung Chen Wen-Juei Jeng Hwai-I Yang Yong Yuan Sheng-Nan Lu I-Shyan Sheen Chen-Hua Liu Cheng-Yuan Peng Jia-Horng Kao Ming-Lung Yu Wan-Long Chuang Chien-Jen Chen |
| author_facet |
Mei-Hsuan Lee Chung-Feng Huang Hsueh-Chou Lai Chun-Yen Lin Chia-Yen Dai Chun-Jen Liu Jing-Houng Wang Jee-Fu Huang Wen-Pang Su Hung-Chih Yang Kwong-Ming Kee Ming-Lun Yeh Po-Heng Chuang Shih-Jer Hsu Ching-I Huang Jung-Ta Kao Chieh-Chang Chen Sheng-Hung Chen Wen-Juei Jeng Hwai-I Yang Yong Yuan Sheng-Nan Lu I-Shyan Sheen Chen-Hua Liu Cheng-Yuan Peng Jia-Horng Kao Ming-Lung Yu Wan-Long Chuang Chien-Jen Chen |
| author_sort |
Mei-Hsuan Lee |
| title |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| title_short |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| title_full |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| title_fullStr |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| title_full_unstemmed |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients |
| title_sort |
clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis c patients |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/e8525597104945a9b652438e850135a1 |
| work_keys_str_mv |
AT meihsuanlee clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chungfenghuang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT hsuehchoulai clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chunyenlin clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chiayendai clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chunjenliu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT jinghoungwang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT jeefuhuang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT wenpangsu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT hungchihyang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT kwongmingkee clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT minglunyeh clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT pohengchuang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT shihjerhsu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chingihuang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT jungtakao clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chiehchangchen clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT shenghungchen clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT wenjueijeng clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT hwaiiyang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT yongyuan clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT shengnanlu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT ishyansheen clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chenhualiu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chengyuanpeng clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT jiahorngkao clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT minglungyu clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT wanlongchuang clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients AT chienjenchen clinicalefficacyandposttreatmentseromarkersassociatedwiththeriskofhepatocellularcarcinomaamongchronichepatitiscpatients |
| _version_ |
1718394369565786112 |